Cerebral Therapeutics

Cerebral Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, directing its efforts toward developing treatments for severe neurological conditions. The company was founded in February 2018 by Dr. Dan Abrams, who brings a unique combination of experience as both a neurosurgeon and a psychiatrist. His prior experience includes founding Sierra Neuropharmaceuticals and serving as the head of Neurosurgery at St. Joseph's Hospital in Denver, providing him with extensive expertise in implantable CNS devices and pharmaceuticals for brain diseases.

The company's core focus is on addressing refractory epilepsy, a condition where patients' seizures are not controlled by existing medical or surgical options. Cerebral Therapeutics is pioneering the use of intracerebroventricular (ICV) therapies, a method that delivers medication directly into the central nervous system. This approach is designed to overcome the limitations of conventional oral medications by bypassing the blood-brain barrier, which can increase the drug's effectiveness at the target site while minimizing systemic side effects and improving patient adherence to treatment regimens. The business model centers on the development and eventual commercialization of these novel drug-device combination therapies. Collaborations with other biopharmaceutical companies are also part of their strategy to advance their pipeline.

The company's main product candidate is CT-010, a proprietary formulation of valproic acid delivered via its proprietary ICVRx™ technology. This system uses a surgically implanted and refillable catheter and pump to provide a continuous, micro-dose infusion of the therapeutic drug directly to the ventricles of the brain. The company has advanced CT-010 into clinical trials, including a Phase 2b double-blind, randomized, placebo-controlled study for treating uncontrolled seizures in patients with medically refractory epilepsy. The company has successfully raised significant capital to fund these developments, including a $40 million Series C financing round in June 2022, bringing its total funding to over $85 million across multiple rounds from investors such as Lynx Capital, RA Capital Management, and Vivo Capital.

Keywords: neurological diseases, refractory epilepsy, intracerebroventricular delivery, CNS drug delivery, neurotherapeutics, biopharmaceutical, clinical-stage, drug-device combination, Dan Abrams, CT-010, valproic acid, blood-brain barrier, central nervous system, neurosurgery, seizure treatment, implanted infusion system, targeted drug delivery, epilepsy therapy, neuroscience, venture-backed, Series C funding, clinical trials, ICV therapy